Do you want to read an article? Please log in or register.
Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study
Hepatology
Indications
Related content
Further Publications
Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study
Hepatology
Aoe K, Tada T, Hiraoka A, Matono T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Nishimura T, Tsuji K, Ishikawa T, Tajiri K, Tanaka H, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Atsushi N, Kosaka H, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tamai H, Komatsu S, Matsuura T, Ueda Y, Kim SK, Ohama H, Tada F, Nakamura S, Nakamura Y, Yoshida O, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Fukunishi S, Tanaka K, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Matsui K, Kaibori M, Okamura J, Fukumoto T, Hiasa Y, Kudo M, Kumada T, RELPEC Group and HCC 48 Group
doi: 10.1097/HEP.0000000000001781
Gastrointestinal Cancer
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Eur J Cancer
Lee PC, Cortellini A, Stefanini B, Yoo C, Chon HJ, Cheon J, Kudo M, Nishida N, Scheiner B, Pinter M, Lombardi P, Fulgenzi CAM, D'Alessio A, Brunetti L, Torkpour A, Valenzi E, Crowley F, Marron TU, Hsu WF, Celsa C, Cabibbo G, Cammà C, Galle PR, Vivaldi C, Masi G, Sharma R, Lin RP, Lin CY, Wietharn B, Saeed A, Tovoli F, Piscaglia F, Dalbeni A, Auriemma A, Sacerdoti D, Parisi A, Manfredi GF, Dondo A, Rimassa L, Pirisi M, Schönlein M, von Felden J, Singal AG, Parkih ND, Andanamala H, Ulahannan S, Roehlen N, Thimme R, Huang YH, Pinato DJ
doi: 10.1016/j.ejca.2026.116749
Gastrointestinal Cancer
Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data
Clin Cancer Res
Campani C, Shim JH, Bouattour M, Touchefeu Y, Delhoume V, Rosmorduc O, Pascale A, An J, Lee HC, Regnault H, Thabut D, Amaddeo G, Ningarhari M, Ollivier-Hourmand I, Métivier C, Ronot M, Ntandaja-Wandji L, Ozenne V, Sidali S, Marra F, Hollande C, Ganne-Carrié N, Nahon P, Peron JM, Lequoy M, Sharma R, Liver Cancer Group P, Allaire M, Nault JC
doi: 10.1158/1078-0432.CCR-25-4943
Gastrointestinal Cancer
Transarterial Chemoembolization in Hepatocellular Carcinoma: Lessons from a 10-Year Real-World Retrospective Study
J Hepatocell Carcinoma
von Schoen-Angerer G, Pesola G, Garo ML, Marini G, Cappio S, Cerny A, Magenta L, Majno-Hurst P, Bernardi L, Cefalì M, Cristaudi A, Terziroli Beretta-Piccoli B, Trevisi E, De Dosso S
doi: 10.2147/JHC.S598858
Inflammatory Bowel Disease
Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE Study
Adv Ther
Privitera G, Palumbo F, Macaluso FS, Laterza L, Pardi V, Viola A, Noviello D, Barberio B, Ricci C, Balestrieri P, Cappello M, Maconi G, Sablich R, Variola A, Bennato R, Pastorelli L, Grossi L, Ribaldone DG, Buda A, Bossa F, Di Sario A, Viscido A, Neri B, Mocci G, Pagnini C, Principi MB, Coletta M, Petruzzellis C, Mazzuoli S, Festa S, Mirarnda A, Bezzio C, Fanigliulo L, Rocco G, Pont ED, Spagnuolo R, Savarino EV, Caprioli FA, Fries W, Ceccarelli L, Scaldaferri F, Orlando A, Testa A, Pugliese D, Armuzzi A
doi: 10.1007/s12325-026-03675-4
Gastrointestinal Cancer
Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab
Eur J Cancer
Vo-Quang E, Campani C, Allaire M, Bouattour M, Regnault H, Marra F, Sutter O, Leroy V, Trepo E, Mouri S, Thabut D, Ozenne V, Sidali S, Hollande C, Boros C, Nahon P, Ganne-Carrié N, Lequoy M, Amaddeo G, Nault JC, Paris Liver Cancer Group
doi: 10.1016/j.ejca.2026.116704
Further Publications
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial
J Gastroenterol Hepatol
Matono T, Tada T, Hiraoka A, Hirooka M, Nakamura Y, Yoshida O, Kariyama K, Nouso K, Tani J, Morishita A, Atsukawa M, Itokawa N, Okubo T, Arai T, Takaguchi K, Tsutsui A, Nagano T, Itobayashi E, Nishimura T, Fukunishi S, Enomoto H, Tsuji K, Tanaka K, Ishikawa T, Tajiri K, Tanaka H, Toyoda H, Koshiyama Y, Ogawa C, Hatanaka T, Kanayama Y, Kakizaki S, Kawata K, Noritake H, Naganuma A, Kosaka H, Matsui K, Kaibori M, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tamai H, Okamura J, Komatsu S, Matsuura T, Nakamura S, Ueda Y, Kim SK, Ohama H, Tada F, Fukumoto T, Hiasa Y, Kudo M, Kumada T
doi: 10.1111/jgh.70422
Inflammatory Bowel Disease
Establishing a Multiple Outcome Set for Crohn's Disease in Real-World Evidence Studies: Results from a Delphi e-Survey
J Crohns Colitis
Moreira PL, Dignass A, Estevinho MM, Santiago M, Reinisch W, Sands BE, D'Haens G, Mantzaris GJ, Danese S, Peyrin-Biroulet L, Dotan I, Jairath V, Magro F, International Organization for the Study of Inflammatory Bowel Diseases (IOIBD)
doi: 10.1093/ecco-jcc/jjaf178
Gastrointestinal Cancer
On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial
Lancet Gastroenterol Hepatol
Kudo M, Ogasawara S, Liu R, Gu S, Wang K, Zhao M, Hu H, Liu Z, Lin K, Liu J, Lin Z, Zhang Y, Peng T, Song J, Ueno M, Zhu J, Bai L, Tong L, Shi Y, Han G, Dong J
doi: 10.1016/S2468-1253(26)00212-8